iBio (IBIO) Current Deferred Revenue (2015 - 2026)
iBio (IBIO) posted quarterly Current Deferred Revenue of $1.2 million for Q1 2026, up 91.67% year-over-year from $600000.0 in Q1 2025, and little changed quarter-over-quarter from $1.2 million in Q4 2025.
iBio (IBIO) Current Deferred Revenue (2015 - 2026) Analysis & Trends
iBio (IBIO) has reported Current Deferred Revenue for 11 consecutive years, with $1.2 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Current Deferred Revenue rose 91.67% year-over-year to $1.2 million; the TTM figure through Mar 2026 stood at $1.2 million (up 91.67% YoY), while the FY2025 annual figure was $1.2 million, up 500.0% from the prior year.
- Current Deferred Revenue steadied at $1.2 million in Q1 2026 per IBIO's latest filing, from $1.2 million in the prior quarter.
- Across five years, Current Deferred Revenue topped out at $1.2 million in Q2 2025 and bottomed at $8000.0 in Q1 2022.
- Historically, Current Deferred Revenue has averaged $537076.9 across 4 years, with a median of $400000.0 in 2024.
- Annual changes were most pronounced in 2022 — Current Deferred Revenue tumbled 99.1% — and 2025, when it surged 500.0%.
- iBio's Current Deferred Revenue stood at $88000.0 in 2022, then soared by 581.82% to $600000.0 in 2024, then surged by 91.67% to $1.2 million in 2025, then changed by 0.0% to $1.2 million in 2026.
- Business Quant data shows IBIO's Current Deferred Revenue at $1.2 million in Q1 2026, $1.2 million in Q4 2025, and $1.2 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | iBio | 172.22 Mn | 172.22 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 1.15 Mn |
| Dec 31, 2025 | 1.15 Mn |
| Sep 30, 2025 | 1.15 Mn |
| Jun 30, 2025 | 1.20 Mn |
| Mar 31, 2025 | 600,000.00 |
| Dec 31, 2024 | 600,000.00 |
| Sep 30, 2024 | 400,000.00 |
| Jun 30, 2024 | 200,000.00 |
| Mar 31, 2024 | 175,000.00 |
| Dec 31, 2022 | 88,000.00 |
| Sep 30, 2022 | 161,000.00 |
| Jun 30, 2022 | 100,000.00 |
| Mar 31, 2022 | 8,000.00 |
| Dec 31, 2021 | 60,000.00 |
| Sep 30, 2021 | 94,000.00 |
| Jun 30, 2021 | 423,000.00 |
| Mar 31, 2021 | 886,000.00 |
| Dec 31, 2020 | 1.23 Mn |
| Sep 30, 2020 | 1.37 Mn |
| Jun 30, 2020 | 1.81 Mn |